INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
INmune Bio Inc. - Common stock (INMB)
Company Research
Source: Yahoo! Finance
Research and Development Expenses: Approximately $20.7 million for 2025, down from $33.2 million in 2024. General and Administrative Expenses: Approximately $10.3 million for 2025, compared to $9.5 million for 2024. Intangible Asset Impairment: Full impairment of $16.5 million in 2025 following Phase 2 Alzheimer's trial results. Cash and Cash Equivalents: Approximately $24.8 million as of December 31, 2025. Shares Outstanding: Approximately 26.6 million shares as of March 30, 2026. Capital Raised: $17.4 million from a registered direct offering and $10.1 million from at-the-market offerings in 2025. Warning! GuruFocus has detected 3 Warning Signs with INMB. Is INMB fairly valued? Test your thesis with our free DCF calculator. Release Date: March 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points INmune Bio Inc ( NASDAQ:INMB ) completed the MINDFuL Alzheimer's trial and advanced CORDStrom t
Show less
Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INMB alerts
High impacting INmune Bio Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
INMB
News
- INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- INmune Bio Inc. Announces 2025 Results and Provides Business UpdateGlobeNewswire
- INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.GlobeNewswire
- INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s DiseaseGlobeNewswire
INMB
Earnings
- 10/30/25 - Beat
INMB
Sec Filings
- 3/30/26 - Form 10-K
- 2/27/26 - Form 8-K
- 2/23/26 - Form 8-K
- INMB's page on the SEC website